Giovanna FATTOVICH. How to predict the outcome of chronic hepatitis B International Hepatitis Conference Paris, January 22 and 23, 2007 Giovanna Fattovich.

Slides:



Advertisements
Similar presentations
Cardiovascular Side Effects of HIV Treatment
Advertisements

Breast Cancer Patient Issues in Family Practice: An Interactive Session.
FibroTest in the diagnosis of HBV
Hepatitis B & Hepatitis C in HIV
Il portatore di HBV: inattivo o malato ?
Overview: Treatment of HCV Infection Jürgen Rockstroh Department of Medicine I, University of Bonn, Germany ICVH Baltimore 20114/22/2011.
Adherence to Hepatitis C Therapies and The Impact of Comorbid Conditions Mary Cassler RPh, MBA, Lon Castle, M.D., Bill Dreitlein, Pharm.D., Mona Khalid,
Slide 1 Healthcare Utilization and Mortality associated with HIV and HCV: How to address the burden of liver disease Susanna Naggie 1,2, Lawrence Park.
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26:
HCV and HBV co-infections Sanjay Bhagani Royal Free Hospital London EACS Advanced Course 2008.
New Paradigms in the management of HIV/HCV co- infected patients Sanjay Bhagani Royal Free Hospital London.
Egyptian Guidelines For Management of Chronic Hepatitis B
SURVIVAL AND LIFE TABLES
Enhanced Hepatitis Strain & Surveillance System (EHSSS) in Review BCCDC Hepatitis Services Site Site Investigator: Liza McGuinness.
1. Interpret a positive HBeAg, Anti- HBcAg, and/or anti-HCV test.
Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ)
HCV Infection in Marginalized Populations
NEW INSIGHT IN HEPATITIS B IN CHILDREN Mei-Hwei Chang, M.D. Department of Pediatrics, National Taiwan University Hospital, Taipei, TAIWAN.
Human Papillomavirus 16: Prevalence, Incidence, and Behavioral Risk Factors Deborah L. Thompson, MD, MSPH March 10, 2004.
Institute for Public Health, Medical Decision Making and Health Technology Assessment 1 Results of the PanEuropean Hepatitis C Project 3 rd Paris Hepatitis.
UK Renal Registry 17th Annual Report Figure 5.1. Trend in one year after 90 day incident patient survival by first modality, 2003–2012 cohorts (adjusted.
©2013 Australian Indigenous HealthInfoNet 1 Key facts Overview of the health of Indigenous people in Western Australia 2013.
When, how and which patient to treat with HBV infection. David Mutimer Queen Elizabeth Hospital Birmingham, England. BSG Post-graduate Course March 20.
HBV and HIV HIV and HBV VG Naidoo Gastroenterology.
Hcv infection and management in advanced liver disease
Alfredo ALBERTI. How to predict outcome in hepatitis C patients Alfredo Alberti Department of Clinical and Experimental Medicine Venetian Institute of.
Professor George KK Lau The University of Hong Kong Hong Kong SAR, China HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated.
The effect of improved HCV diagnosis and treatment on public health The effect of improved HCV diagnosis and treatment on public health P Mathurin Hôpital.
CORRELATION BETWEEN HBSAG LEVEL AND VIRAL LOAD
Natural History of Hepatitis B and Liver Cancer Screening Herbert H Lee, M.D., M.P.H., M.S.Ed.
The Natural History of Delta Hepatitis Prof. Dr. Cihan Yurdaydin University of Ankara Medical School Gastroenterology Department EASL Monothematic Conference.
Hepatitis B: Epidemiology
Protein GP73 (GOLGI PROTEIN 73) A NEW NON-INVASIVE BIOMARKER FOR ASSESSING LIVER FIBROSIS AND RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA N.K. Gatselis,
1 Hepatitis B Treatment Dr R.V.S.N.Sarma., M.D., Consultant Physician & Chest Specialist.
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
Clinicaloptions.com/hepatitis Serum HBsAg as a Predictor of Response to PegIFN in HBeAg-Positive Patients Slideset on: Chan HL, Wong VW, Chim AM, Chan.
Hepatitis B Virus Dr R V S N Sarma., M.D., [SLIDE 1] Title Slide
HBV genotyping 12/21/07 Carrie Marshall. Received a send-out request for HBV genotyping on a 52y man.
1. Sustained suppression of HBV replication Decrease in serum HBV DNA to
FT in prognostic of HBV FibroTest: predictive value in HBV.
Hepatitis B: A Crash Course Yu-Ming Chang October 21, 2014.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2012.
Treating HBV Infection: Sustained Remission with Immune control Joseph Sung MD, PhD Department of Medicine and Therapeutics Institute of Digestive Diseases.
Sources of Hepatitis C Infection (U.S.) Previously Acquired (
Hepatitis B The Basics David Wong University of Toronto March 2005.
Hepatocellular carcinoma related to Hbv and Hcv
HBV Factors and Clinical Outcomes M Omata. Genotypes in China and Japan.
Milan J. Sonneveld,1 Bettina E. Hansen, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Edward Gane, Yun-Fan Liaw, Qing Xie, E. Jenny Heathcote, Henry.
내과스텝강의 국내 만성B형간염의 현황과 치료 전략.
Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
Setting the Scene. Non A, non B Hepatitis  Early 1970’s recognised that 2/3 of post transfusional hepatitis were –ve for both Hep A & Hep B Non Hep A.
Clinicaloptions.com/hepatitis Using Virologic and Serologic Tests in the Management of Hepatitis B Diagnose chronic HBV infection When in slideshow mode,
F. 정 회 훈 Am J Gastroenterol 2012;107:46-52 Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy:
HBV. Overview of the Epidemiology of Hepatotropic Viruses.
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Viral Hepatitis.
Treatment of HBV/HCV Coinfection
Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen–Positive Patients with Chronic Hepatitis B : A Randomized International Study of Entecavir.
Dr Iyat Abdul Sattar A study on the clinical & serolological markers of HBV among patients with chronic HBV infection in Babylon Dr Monem Makki Alshok.
Clinical outcome after SVR: Veterans Affairs
Hepatology Hepatitis C virus (HCV) genotype 1b as a risk factor
Natural history of hepatitis B
Suna Yapali, Nizar Talaat, Anna S. Lok 
Impact of metabolic risk factors on HCC
Clinicaloptions.com/hepatitis Using Virologic and Serologic Tests in the Management of Hepatitis B Diagnose chronic HBV infection When in slideshow mode,
Progression of chronic Hepatitis B From beginning to end
Incidence of HCC after HCV treatment with DAAs: ERCHIVES
Presentation transcript:

Giovanna FATTOVICH

How to predict the outcome of chronic hepatitis B International Hepatitis Conference Paris, January 22 and 23, 2007 Giovanna Fattovich Department of Gastroenterology, University of Verona, Italy

How to predict HBeAg seroconversion * older age Higher ALT levels at presentation acute flares of hepatitis HBV genotype (B > C) severe CH HBeAg+anti-HBe years ALT Chu CM, J Hepatol 2005: 43: 411 * strong association with higher rates Genotype B Genotype C years

Hsu 2002 Manno 2004 Bortolotti 2006 Fattovich 2007 RaceAsiansCaucasians Clinical settingclinicBlood donors clinic (children) clinic Number patients Median Follow-up (yrs) Histologic deterioration 0.06nr00 HCC a 00.2 b Liver-related death c 00.2 HBsAg loss a alcohol consumption > 60g/die; b 2 pts with cirrhosis occurrence before HBeAg seroclearance; c 2 HCC, 1 alcoholic cirrhosis; nr = not reported Morbidity and mortality in inactive HBsAg carriers incidence per 100 person years of major events

How to predict the outcome of CHB: effect of HBsAg loss mean follow-up: 5 to 6 yrs Eurohep, Am J Gastroenterol 1998; 93: A B A.Patients who did not clear HBsAg B.Patients who cleared HBsAg P = % Probability of HCC occurrence in cirrhosis B 0 Yrs AuthorPopulationStatus at clearance N° PtsAny liver-related complications/death Eurohep 1998Caucasianscirrhosis3222% Chen 2002Asianscirrhosis2917% No cirrhosis1892.1% * Arase 2006Asianscirrhosis673% No cirrhosis1670 * only those with HCV co-infection Risk of HCC after HBsAg loss - cirrhosis - HCV coinfection Higher risk of HCC in cirrhotics with older age at HBsAg loss

Natural history of cirrhosis type B Annual incidence decompensation 3-4% Annual incidence HCC 2-3% EASL International Consensus Conference on Hepatitis B, yrs probability in compensated cirrhosis :80-85% 5-yrs probability in compensated cirrhosis :80-85% 5-yrs probability after decompensation: 15-30% 5-yrs probability after decompensation: 15-30% Survival % HCC survival decompensation Fattovich G, Am J Gastroenterol 2002 Causes of liver-related death HCC 40 % Liver failure/VB60 %

HOST EXTERNAL FACTORS VIRUS How to predict the outcome of chronic hepatitis B Factors influencing progression to cirrhosis, HCC and liver-related death Levels of HBV-DNA replication HBV genotype HBV variant

* Adjusted for age, sex, cigarette smoking, and alcohol consumption < HBV DNA copies/mL All Participants (n = 3582) * RR * (95% CI) *P < > 10 6 * * HBeAg(-), Normal ALT (n = 2923) < > 10 6 HBV DNA copies/mL *P <.001 * * * Level of HBV DNA (PCR-assays) at entry & progression to cirrhosis in population-based cohort studies 3582 HBsAg untreated asian carriers mean follow-up 11 yrs 365 patients newly diagnosed with cirrhosis Iloeje UH, Gastroenterology 2006; 130: HBV-DNA viral load (> 10 4 cp/ml) strongest predictor of progression to cirrhosis independent of ALT and HBeAg status HBV-DNA status only at entry, NOT at the time of diagnosis of cirrhosis

HBV-DNA levels (> 10 4 cp/ml) strong predictor of HCC, independent of HBeAg, ALT and cirrhosis Entire cohort (N = 3653) HBV-DNA (cp/ml)RR < x x 10 5 > 1.0 x Subcohort (N = 2925) HBV-DNA (cp/ml)RR < x x 10 5 > 1.0 x Population based cohort study of HBsAg asian carriers, mean follow-up= 11.4 Chen CJ et al JAMA 2006;295: % 7.9 % 0.9 % 0.7 % 3.1 % >6log 5-6log 4-5log <4log Level of HBV DNA (PCR-assays) at entry & risk of HCC HBeAg ( ), Normal ALT, No cirrhosis at entry (n = 2925) >6log 5-6log 4-5log <4log 14.9% 12.1% 3.5% 1.3% Entire cohort (n = 3653)

Persistent HBV DNA Associated With Increased HCC Risk *Cox proportional hazards models. Risk is relative to < 10 4 copies/mL at entry/not tested at follow-up. Data adjusted for sex, age, cigarette smoking, and alcohol consumption. Adjusted Hazard Ratio* for HCC (95% CI) Low < 10 4 Mid High 10 5 HBV DNA (copies/mL) High 10 5 DNA at entry: DNA at follow-up: n = Chen CJ, et al. JAMA. 2006;295:65-73.

Compensated cirrhosis type B independent factors affecting liver-related mortality Age Albumin Bilirubin Platelets Splenomegaly HBeAg Factors Realdi, J Hepatol 1994 Age AST/ALT ratio Viral status adjusted RR= 5.9 in HBV DNA+ vs HBV DNA- Factors Fattovich, Am J Gastroenterol 2002

VariableRR Cirrhosis Genotype C (vs B) HBV genotype & risk of HCC Increased HCC risk among Chinese patients with genotype C vs genotype B Genotype B more common than genotype C in younger non-cirrhotic pts with HCC (Taiwan) CH genotype > 50 yrs B B C C B C B C cirrhosis< 50 HCC % * p=0.03 * * Chan, Gut 2004 Yu, J Natl Cancer Inst 2005 Mahmood, Liver Int 2005 Kao, Gastroenterology 2000 Ni, Gastroenterology 2004 Chen CH, Hepatogastroenterology 2004 Cirrhosis + genotype C Cirrhosis + genotype B

VIRUS HOST EXTERNAL FACTORS VIRUS Older age at diagnosis, Older age at anti-HBe seroconversion Male gender Recurrent flares of hepatitis HCC Presence of cirrhosis Family history of HCC Race (Asian, African) How to predict the outcome of chronic hepatitis B Factors influencing disease progression

VIRUS HOST EXTERNAL FACTORS VIRUS How to predict the outcome of chronic hepatitis B Factors influencing disease progression Concurrent infections (HCV, HDV, HIV) Alcohol consumption Comorbidities (diabetes, obesity ….) Aflatoxin Smoking

The association between diabetes and HCC El Serag, Clinical Gastroenterol Hepatol 2006; 4: Pooled risk estimates and 95% CIs of studies grouped according to study design, geographic location, and control group selection Not all studies controlled for confounding risk factors adequately (eg, HBV, HCV, alcohol, obesity ….) Unclear whether diabetes preceded the underlying chronic liver disease The association between diabetes and HCC requires more research

Some population-based cohort studies from Europe and USA found that obesity is associated with a 2-4 fold increased HCC risk, however these studies ….. did not control for confounding risk factors (eg. HBV, HCV, alcohol, diabetes) (Moller, 1994) Or controlled only for alcoholism and diabetes (Calle, 2003; Samanic, 2004) Or found no increased risk when excluding pts with diabetes (Wolk, 2001) A USA cohort study of OLT candidates found that obesity was an independent risk factor for HCC in alcoholic cirrhosis (OR 3) and cryptogenic cirrhosis (OR 11), but not in HBV and HCV-related cirrhosis (Nair, 2002) The association between obesity and HCC No definitive conclusion can be drawn as to the role of obesity as a risk factor for HCC per se or as a cofactor in chronic hepatitis B Adapted from Donato & Fattovich, Oncogene 2006 ; 25:

Persistent high level of HBV replication and long duration of active hepatitis are the best predictors of adverse clinical outcome (cirrhosis, HCC and liver- related mortality) Sustained suppression of HBV replication (inactive carrier state) before the onset of cirrhosis confers favorable prognosis (with similar survival compared to uninfected individuals in caucasians) Sustained suppression of HBV replication in cirrhotic patients lowers the risk of HCC How to predict the outcome of CHB: conclusions

Older age, male gender, multiple ALT flares, severity of compensated cirrhosis at diagnosis, concurrent viral infections and alcohol abuse are additional predictors of disease progression Growing evidence suggest that HBV genotypes may influence different clinical outcomes, but their role in HBV- related liver disease needs to better defined Further studies are needed to investigate other viral factors (eg HBV mutant) and preventable or treatable comorbidities (eg diabetes, obesity) in the prognosis of chronic hepatitis B This scenario suggests that an efficient treatment of chronic hepatitis B should shorten the highly replicative phase and counseling could prevent comorbidity How to predict the outcome of CHB: conclusions